ORIC Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, ORIC Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
ORIC Pharmaceuticals: 7 sponsored US clinical trials, 3 recruiting.
ORIC Pharmaceuticals sponsors 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Solid Tumors, with 2 trials.
Upper-quartile sponsor footprint
ORIC Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC
NCT06816992
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
NCT05413421
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
NCT05315700
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
NCT05227144
Study of ORIC-101 in Combination With Enzalutamide
NCT04033328
Study of ORIC-101 in Combination With Anticancer Therapy
NCT03928314
Study of ORIC-101 in Healthy Adult Subjects
NCT03324555
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
Therapeutic Areas
What is open in the ORIC Pharmaceuticals pipeline
3 recruiting of 7 indexed (43% open); 2 completed (29%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Solid Tumors (2 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ORIC Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 7 registered trials and 43% open enrollment, not the therapeutic-area sidebar.
ORIC Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 43% open enrollment (± trial volume)
- Alphatec Spine · 43% recruiting · 7 trials
- Clarity Pharmaceuticals · 43% recruiting · 7 trials
- Colorado Center for Reproductive Medicine · 43% recruiting · 7 trials
- David Moss · 43% recruiting · 7 trials
Related
What to do with this ORIC Pharmaceuticals page
7 registered trials is a research-attention snapshot, not an endorsement of ORIC Pharmaceuticals or any single study.
- 3 of ORIC Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Solid Tumors is the condition ORIC Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ORIC Pharmaceuticals pipeline card: 7 registered trials from official public datasets.Report a data error.